Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials

Levodopa-carbidopa intestinal gel (LCIG) provides continuous infusion and reduces “off” time in advanced Parkinson's disease (PD) patients with motor fluctuations despite optimized pharmacotherapy. Clinical experience with 2 LCIG dosing paradigms from phase 3 studies was examined. In an open-la...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Parkinsonism & related disorders Jg. 21; H. 7; S. 742 - 748
Hauptverfasser:	Lew, Mark F., Slevin, John T., Krüger, Rejko, Martínez Castrillo, Juan Carlos, Chatamra, Krai, Dubow, Jordan S., Robieson, Weining Z., Benesh, Janet A., Fung, Victor S.C.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.07.2015
Schlagworte:	Antiparkinson Agents - administration & dosage Antiparkinson Agents - metabolism Carbidopa - administration & dosage Carbidopa - metabolism Dosing Double-Blind Method Drug Combinations Female Gels Humans Internationality Intestinal Absorption - drug effects Intubation, Gastrointestinal - methods Jejunum - drug effects Jejunum - metabolism Levodopa - administration & dosage Levodopa - metabolism Levodopa-carbidopa intestinal gel Male Motor fluctuations Neurology Parkinson's disease PEG-J procedure Motor fluctuations Dosing PEG-J procedure Levodopa-carbidopa intestinal gel Parkinson's disease
ISSN:	1353-8020, 1873-5126, 1873-5126
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!